cbg

Cannabigerol (CBG) is a non-intoxicating cannabinoid, meaning it doesn’t produce the “highs” that are synonymous with THC. Because it is present in low levels (usually less than 1%) in most cannabis strains, CBG is considered a minor cannabinoid. Amazingly, however, THC and CBD start out as CBG—it’s the chemical parent of THC and CBD. Cannabis plants produce cannabigerolic acid (CBGA), the precursor to the three main cannabinoid lines: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA).
CBG is thought to be particularly effective in treating glaucoma because it reduces intraocular pressure.
In animal experiments involving mice, CBG was found to be effective in decreasing the inflammation characteristic of inflammatory bowel disease.
CBG was shown to protect neurons in mice with Huntington’s disease.
CBG is showing great promise as a cancer fighter. Specifically, CBG was shown to block receptors that cause cancer cell growth.
European research shows evidence that CBG is an effective antibacterial agent.
In a very recent 2017 study, researchers showed that a form of CBG purified to remove delta-9 THC was a very effective appetite stimulant in rats.
In a study that looked at the effects of five different cannabinoids on bladder contractions, CBG tested best at inhibiting muscle contractions, so it may be a future tool in preventing bladder dysfunction disorders.